110 related articles for article (PubMed ID: 16641922)
1. Biochemical validation of a rat model for polycystic kidney disease: comparison of guanidino compound profile with the human condition.
Torremans A; Marescau B; Kränzlin B; Gretz N; Billiouw JM; Vanholder R; De Smet R; Bouwman K; Brouns R; De Deyn PP
Kidney Int; 2006 Jun; 69(11):2003-12. PubMed ID: 16641922
[TBL] [Abstract][Full Text] [Related]
2. Renal handling of guanidino compounds in rat and rabbit.
Levillain O; Marescau B; De Deyn PP
J Physiol; 1997 Mar; 499 ( Pt 2)(Pt 2):561-70. PubMed ID: 9080382
[TBL] [Abstract][Full Text] [Related]
3. Influence of 72% injury in one kidney on several organs involved in guanidino compound metabolism: a time course study.
Levillain O; Marescau B; Possemiers I; Al Banchaabouchi M; De Deyn PP
Pflugers Arch; 2001 Jul; 442(4):558-69. PubMed ID: 11510889
[TBL] [Abstract][Full Text] [Related]
4. Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat.
Braun C; Kleemann T; Hilgenfeldt U; Riester U; Rohmeiss P; van der Woude FJ
Kidney Int; 2002 Jun; 61(6):2149-56. PubMed ID: 12028455
[TBL] [Abstract][Full Text] [Related]
5. Dehydration modifies guanidino compound concentrations in the different zones of the rat kidney.
Levillain O; Marescau B; Possemiers I; De Deyn P
Pflugers Arch; 2002 May; 444(1-2):143-52. PubMed ID: 11976926
[TBL] [Abstract][Full Text] [Related]
6. Transgenic overexpression of prothymosin alpha induces development of polycystic kidney disease.
Li KJ; Shiau AL; Chiou YY; Yo YT; Wu CL
Kidney Int; 2005 May; 67(5):1710-22. PubMed ID: 15840017
[TBL] [Abstract][Full Text] [Related]
7. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency.
Marescau B; Nagels G; Possemiers I; De Broe ME; Becaus I; Billiouw JM; Lornoy W; De Deyn PP
Metabolism; 1997 Sep; 46(9):1024-31. PubMed ID: 9284891
[TBL] [Abstract][Full Text] [Related]
8. Parallel analysis of mRNA and microRNA microarray profiles to explore functional regulatory patterns in polycystic kidney disease: using PKD/Mhm rat model.
Dweep H; Sticht C; Kharkar A; Pandey P; Gretz N
PLoS One; 2013; 8(1):e53780. PubMed ID: 23326503
[TBL] [Abstract][Full Text] [Related]
9. Renal expression of FGF23 and peripheral resistance to elevated FGF23 in rodent models of polycystic kidney disease.
Spichtig D; Zhang H; Mohebbi N; Pavik I; Petzold K; Stange G; Saleh L; Edenhofer I; Segerer S; Biber J; Jaeger P; Serra AL; Wagner CA
Kidney Int; 2014 Jun; 85(6):1340-50. PubMed ID: 24402093
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of methylguanidine and changes in guanidino compound levels in plasma, urine, and kidneys of furosemide-treated rats.
Levillain O; Marescau B; Possemiers I; De Deyn PP
Metabolism; 2008 Jun; 57(6):802-10. PubMed ID: 18502263
[TBL] [Abstract][Full Text] [Related]
11. Effects of starvation on guanidino compound metabolism in mice.
Shindo S; Watanabe Y; Mori A
Res Commun Chem Pathol Pharmacol; 1986 Oct; 54(1):73-85. PubMed ID: 3797807
[TBL] [Abstract][Full Text] [Related]
12. Serum guanidino compound levels in uremic pediatric patients treated with hemodialysis or continuous cycle peritoneal dialysis. Correlations between nerve conduction velocities and altered guanidino compound concentrations.
De Deyn PP; Robitaille P; Vanasse M; Qureshi IA; Marescau B
Nephron; 1995; 69(4):411-7. PubMed ID: 7777105
[TBL] [Abstract][Full Text] [Related]
13. Metabolic pathway of guanidino compounds in chronic renal failure.
Mikami H; Orita Y; Ando A; Fujii M; Kikuchi T; Yoshihara K; Okada A; Abe H
Adv Exp Med Biol; 1982; 153():449-58. PubMed ID: 7164918
[No Abstract] [Full Text] [Related]
14. Guanidino compounds that are increased in cerebrospinal fluid and brain of uremic patients inhibit GABA and glycine responses on mouse neurons in cell culture.
De Deyn PP; Macdonald RL
Ann Neurol; 1990 Nov; 28(5):627-33. PubMed ID: 2135950
[TBL] [Abstract][Full Text] [Related]
15. Guanidino compounds generate reactive oxygen species.
Mori A; Kohno M; Masumizu T; Noda Y; Packer L
Biochem Mol Biol Int; 1996 Sep; 40(1):135-43. PubMed ID: 8886279
[TBL] [Abstract][Full Text] [Related]
16. Age-Related Alterations in Blood Biochemical Characterization of Hepatorenal Function in the PCK Rat: A Model of Polycystic Kidney Disease.
Shimomura Y; Brock WJ; Ito Y; Morishita K
Int J Toxicol; 2015; 34(6):479-90. PubMed ID: 26503599
[TBL] [Abstract][Full Text] [Related]
17. Autoregulation of renal blood flow and pressure-dependent renin release in autosomal dominant polycystic kidney disease of rats.
Braun C; Lüdicke C; Rebsch W; Gretz N; van der Woude FJ; Rohmeiss P
Nephrol Dial Transplant; 1996; 11 Suppl 6():52-7. PubMed ID: 9044329
[TBL] [Abstract][Full Text] [Related]
18. Guanidino compound levels in brain regions of non-dialyzed uremic patients.
De Deyn PP; Marescau B; D'Hooge R; Possemiers I; Nagler J; Mahler C
Neurochem Int; 1995 Sep; 27(3):227-37. PubMed ID: 8520461
[TBL] [Abstract][Full Text] [Related]
19. The pck rat: a new model that resembles human autosomal dominant polycystic kidney and liver disease.
Lager DJ; Qian Q; Bengal RJ; Ishibashi M; Torres VE
Kidney Int; 2001 Jan; 59(1):126-36. PubMed ID: 11135065
[TBL] [Abstract][Full Text] [Related]
20. Guanidino compounds and hemodialysis.
Ochiai Y; Abe S; Yamada T; Tada K; Kosaka F
Adv Exp Med Biol; 1982; 153():459-64. PubMed ID: 7164919
[No Abstract] [Full Text] [Related]
[Next] [New Search]
